Al-Abbadi Mousa A, Barroca Helena, Bode-Lesniewska Beata, Calaminici Maria, Caraway Nancy P, Chhieng David F, Cozzolino Immacolata, Ehinger Mats, Field Andrew S, Geddie William R, Katz Ruth L, Lin Oscar, Medeiros L Jeffrey, Monaco Sara E, Rajwanshi Arvind, Schmitt Fernando C, Vielh Philippe, Zeppa Pio
Department of Pathology, Microbiology and Forensic Medicine, the University of Jordan, Amman, Jordan.
Serviço de Anatomia Patológica, Hospital S João-Porto, Porto, Portugal.
Acta Cytol. 2020;64(4):306-322. doi: 10.1159/000506497. Epub 2020 May 26.
The evaluation of lymph nodes (LN) by fine-needle aspiration cytology (FNAC) is routinely used in many institutions but it is not uniformly accepted mainly because of the lack of guidelines and a cytopathological diagnostic classification. A committee of cytopathologists has developed a system of performance, classification, and reporting for LN-FNAC.
The committee members prepared a document that has circulated among them five times; the final text has been approved by all the participants. It is based on a review of the international literature and on the expertise of the members. The system integrates clinical and imaging data with cytopathological features and ancillary techniques. The project has received the endorsement and patronage of the International Academy of Cytology and the European Federation of the Cytology Societies.
Clinical, imaging, and serological data of lymphadenopathies, indications for LN-FNAC, technical procedures, and ancillary techniques are evaluated with specific recommendations. The reporting system includes two diagnostic levels. The first should provide basic diagnostic information and includes five categories: inadequate/insufficient, benign, atypical lymphoid cells of undetermined/uncertain significance, suspicious, and malignant. For each category, specific recommendations are provided. The second diagnostic level, when achievable, should produce the identification of specific benign or malignant entities and additional information by utilizing ancillary testing.
The authors believe that the introduction of this system for performing and reporting LN-FNAC may improve the quality of the procedure, the report, and the communication between cytopathologists and the clinicians. This system may lead to a greater acceptance and utilization of LN-FNAC and to a better interdisciplinary understanding of the results of this procedure.
在许多机构中,细针穿刺细胞学检查(FNAC)用于评估淋巴结(LN)是常规操作,但由于缺乏指南和细胞病理学诊断分类,该方法并未得到一致认可。一个细胞病理学家委员会已经开发出一套用于LN-FNAC的操作、分类和报告系统。
委员会成员编写了一份文件,在他们之间传阅了五次;最终文本已得到所有参与者的批准。该系统基于对国际文献的综述以及成员的专业知识。它将临床和影像学数据与细胞病理学特征及辅助技术相结合。该项目已获得国际细胞学会和欧洲细胞学会联合会的认可与支持。
对淋巴结病的临床、影像学和血清学数据、LN-FNAC的适应证、技术操作及辅助技术进行了评估,并给出了具体建议。报告系统包括两个诊断级别。第一级应提供基本诊断信息,包括五类:不充分/不足、良性、意义未明/不确定的非典型淋巴细胞、可疑和恶性。针对每一类都提供了具体建议。第二级诊断,在可行的情况下,应通过利用辅助检测来明确特定的良性或恶性实体并提供额外信息。
作者认为,引入这套用于LN-FNAC操作和报告的系统可能会提高该操作、报告的质量,以及细胞病理学家与临床医生之间的沟通。该系统可能会使LN-FNAC得到更广泛的接受和应用,并增进对该操作结果的跨学科理解。